Zacks Investment Research lowered shares of DBV Technologies S.A. (NASDAQ:DBVT) from a buy rating to a hold rating in a research note issued to investors on Friday morning.

According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “

A number of other analysts have also issued reports on DBVT. Jefferies Group LLC reiterated a buy rating and set a $47.00 price target on shares of DBV Technologies in a research note on Thursday, June 1st. BidaskClub lowered shares of DBV Technologies from a sell rating to a strong sell rating in a research note on Wednesday, June 14th. Deutsche Bank AG started coverage on shares of DBV Technologies in a research note on Friday, June 23rd. They set a buy rating and a $46.00 price target on the stock. ValuEngine upgraded shares of DBV Technologies from a sell rating to a hold rating in a research note on Saturday, June 24th. Finally, HC Wainwright reiterated a buy rating and set a $50.00 price target on shares of DBV Technologies in a research note on Thursday, July 6th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. DBV Technologies currently has an average rating of Buy and an average target price of $51.00.

DBV Technologies (NASDAQ:DBVT) traded up 0.33% on Friday, reaching $42.44. 172,795 shares of the company’s stock were exchanged. DBV Technologies has a one year low of $31.87 and a one year high of $46.33. The stock’s market cap is $1.95 billion. The firm has a 50 day moving average of $44.06 and a 200-day moving average of $37.85.

ILLEGAL ACTIVITY WARNING: “DBV Technologies S.A. (DBVT) Downgraded to “Hold” at Zacks Investment Research” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/dbv-technologies-s-a-dbvt-downgraded-to-hold-at-zacks-investment-research/1599444.html.

A number of large investors have recently modified their holdings of DBVT. Parametric Portfolio Associates LLC increased its stake in DBV Technologies by 9.2% during the first quarter. Parametric Portfolio Associates LLC now owns 33,270 shares of the company’s stock worth $1,172,000 after purchasing an additional 2,794 shares during the period. Victory Capital Management Inc. purchased a new stake in shares of DBV Technologies during the first quarter worth approximately $303,000. Alliancebernstein L.P. increased its stake in shares of DBV Technologies by 21.1% during the first quarter. Alliancebernstein L.P. now owns 996,535 shares of the company’s stock worth $35,098,000 after buying an additional 173,798 shares during the period. MARSHALL WACE ASIA Ltd purchased a new stake in shares of DBV Technologies during the first quarter worth approximately $3,566,000. Finally, Marshall Wace North America L.P. purchased a new stake in shares of DBV Technologies during the first quarter worth approximately $3,566,000. Institutional investors own 45.52% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with Analyst Ratings Network's FREE daily email newsletter.